Key Takeaways
- Investment firm Oppenheimer has launched coverage on AEHR with an Outperform designation and set a $120 price objective
- Shares currently sit at $95.56, reflecting a remarkable 373% gain year-to-date
- The company’s Sonoma solution is scaling up through a partnership with a major hyperscaler, backed by a record-breaking $41 million contract
- Aehr’s FOX-XP technology has moved into mass production with a prominent AI chip manufacturer, supported by a $22 million additional purchase
- The investment firm anticipates fiscal year 2027 and 2028 revenues reaching $141 million and $218 million
Oppenheimer launched its coverage of Aehr Test Systems (AEHR) this Wednesday, assigning an Outperform designation alongside a $120 price objective, drawing investor attention even as the stock experienced a 4.4% decline in pre-market activity.
Shares are presently valued at $95.56, having surged 373% since the beginning of the year and gaining 128% across the last six-month period.
According to analyst Edward Yang, the company’s burn-in testing systems evaluate semiconductors under stress conditions to identify potential failures before deployment or expensive packaging processes. The investment firm anticipates that increasing power requirements and package costs will elevate the expense of late-stage failures, positioning Aehr for significant growth amid the AI revolution.
The Sonoma product line is currently scaling operations with a prominent hyperscaler client via a landmark $41 million purchase order. This represents substantial validation from a leading player in artificial intelligence infrastructure.
FOX-XP Platform Achieves Mass Production Milestone
Aehr’s FOX-XP technology has recently transitioned to mass production status with a significant AI processor manufacturer. This achievement was accompanied by an additional $22 million order, contributing to an order backlog that now exceeds $100 million.
The investment firm projects revenues of $141 million for fiscal year 2027 and $218 million for fiscal 2028. Oppenheimer’s second-quarter fiscal 2027 projection exceeds market consensus, fueled by anticipated Sonoma expansion.
Analysis from InvestingPro indicates that market watchers are forecasting 181% revenue expansion for fiscal 2027. Three financial analysts have recently increased their earnings projections.
Oppenheimer recognized that the current valuation appears elevated. InvestingPro analysis suggests the stock may be overpriced compared to its Fair Value calculation, trading at a premium revenue multiple.
Potential FOX Platform Expansion
However, Yang emphasized that present forecasts provide minimal consideration for the possibility of FOX securing a second major AI processor manufacturer as a client. Even one additional AI chip producer implementing FOX for mass production could necessitate acquisition of dozens of testing systems.
Should this scenario materialize, the analyst believes it could significantly elevate AEHR’s profit potential.
Aehr’s fiscal 2026 financial performance featured record quarterly bookings totaling $60.7 million. Management issued fiscal 2027 revenue guidance spanning $130 million to $150 million.
Following these results, Freedom Broker elevated AEHR from Hold to Buy status while increasing its price objective to $110. Jefferies similarly initiated coverage with a Buy recommendation and a $175 target, highlighting the company’s pivot toward AI manufacturing.
The company has scheduled delivery of its FOX-XP systems throughout the upcoming six-month period to a mass production facility located in Taiwan.
Additionally, Aehr secured a subsequent order for a FOX-XP multi-wafer testing system from its primary silicon photonics client, with delivery anticipated during the first half of 2027.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
